Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PsiOxus to Release Study Results of Oncolytic Vaccine Enadenotucirev

Published: Saturday, May 17, 2014
Last Updated: Saturday, May 17, 2014
Bookmark and Share
Phase I studies to be presented at 2014 ASCO annual meeting.

PsiOxus Therapeutics, Ltd. (PsiOxus) has announced that two of its on-going phase I studies of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting to be held 30 May to 3 June, 2014 in Chicago, Illinois.

The EVOLVE (EValuating OncoLytic Vaccine Efficacy) trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers and the MoA (Mechanism of Action) trial is a phase I “window of opportunity” trial evaluating intravenous and intra-tumoural administration of enadenotucirev to patients with colon cancer.

Enadenotucirev is an oncolytic Ad11/Ad3 chimeric group B adenovirus that has previously been shown to selectively destroy metastatic solid tumours at low concentrations in pre-clinical models.

To date, a combined total of 46 cancer patients have been dosed with up to four cycles (12 doses) of enadenotucirev. An independent Data Safety Monitoring Committee has approved the proposed dose to be taken into phase 2 clinical trials for both single cycle and repeat cycle administration. This safety data will be presented at the ASCO meeting.

Intra-tumoural delivery of oncolytic viruses to superficial tumour sites has been shown to be clinically successful in phase III clinical trials, but systemic delivery of viruses to metastatic tumour sites via intravenous delivery has been more elusive.

In the two PsiOxus studies, the ability to selectively deliver the live replicating virus to tumour cells has been examined by a number of techniques including positron emission tomography scans, immunohistochemistry, quantitative polymerase chain reaction assays, and viral plaque assays.

• Dr Emiliano Calvo will present A First in Human Phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumours (poster board 170) at ASCO on Sunday, June 1 in S Hall A2 from 8:00 a.m. to 11:45 a.m.

• Dr Rocio Garcia Carbonero will present Phase 1 Mechanism of Action Study of Intra-tumoral or Intravenous Administration of enadenotucirev, an Oncolytic Ad11/Ad3 Chimeric group B Adenovirus in Colon Cancer Patients Undergoing Resection of Primary Tumour (poster board 178B) at ASCO on Sunday, June 1 in S Hall A2 from 8:00 a.m. to 11:45 a.m.

Dr John Beadle, CEO of PsiOxus, commented: “We are looking forward to the presentation of these clinical study results as we assess the safety profile of enadenotucirev as well as intravenous delivery of this oncolytic vaccine to cancer cells in patients. We remain on track to initiate phase II study later this year.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Myotec Merges with Hybrid Biosystems to Form PsiOxus Therapeutics
Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces the merger of its portfolio company Myotec Therapeutics Ltd. (Myotec) with Hybrid Biosystems Ltd. (Hybrid) to form PsiOxus Therapeutics.
Wednesday, December 15, 2010
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!